Carlyle Group will purchase a 20% stake in Indian billionaire Ajay Piramal’s pharmaceutical business, according to an exchange filing.
The private equity fund will pay $490 million for the holding, valuing the business at an enterprise value of $2.7 billion. In addition to helping expand capacity of the pharmaceutical operations, the Piramal group will use the money to repay some of parent Piramal Enterprises Ltd.’s debt, the filing said.
“This infusion of funds will further strengthen our balance sheet and provide us with a war chest for the next phase of our strategy,” Ajay Piramal, chairman of Piramal Enterprises, said in the filing.
In May, Carlyle agreed to buy up to 74% of SeQuent Scientific, the largest pure-play animal healthcare company in India.
Source: Bloomberg
Can’t stop reading? Read more
CVC taps ex-EE chief Marc Allera to lead newly launched sports investment platform
CVC taps ex-EE chief Marc Allera to lead newly launched sports investment platform CVC Capital...
Private equity leads surge as European demand for alternatives hits new highs, says Neuberger Berman
Private equity leads surge as European demand for alternatives hits new highs, says Neuberger...
Quintet Private Bank deepens BlackRock partnership to boost private markets access
Quintet Private Bank deepens BlackRock partnership to boost private markets access Quintet Private...